Inside 2026: The Industry’s AI Turning Point
The life sciences sector is bracing for a year when AI delivers real returns, regulators move faster, and trial operations are finally built for modern science.
False
The life sciences sector is bracing for a year when AI delivers real returns, regulators move faster, and trial operations are finally built for modern science.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
October 22, 2026
5 min read
Rob DiCicco discusses how FDA–industry collaboration is helping sponsors rethink safety reporting, selective safety data collection, and pragmatic clinical trial design.
October 12, 2026
2 min read
“Caribou’s story has taken a heartbreaking turn,” says CEO Rachel Haurwitz, with the CRISPR-focused biotech set to discontinue vispa-cel and CB-011, and reduce its workforce
October 12, 2026
5 min read
Bayer plans a $2.2 billion Ohio campus, Genentech breaks ground in Oregon, and new investments support vaccine production, downstream processing, and manufacturing in orbit
October 8, 2026
2 min read
Adicet Bio reports 12-month remission and renal response data for its allogeneic gamma delta CAR T therapy
False
Affiliations:
Specialties:
Areas of Expertise: